Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: A randomized controlled trial
AIDS, Volume 20, No. 18, Year 2006
Notification
URL copied to clipboard!
Description
OBJECTIVE: To demonstrate a causal relationship between herpes simplex virus 2 (HSV-2) and increased genital HIV-1-RNA shedding in women on HAART. DESIGN: A randomized, double-blind, placebo-controlled trial of herpes-suppressive therapy (valacyclovir 500 mg twice a day) in HIV-1/HSV-2-infected women taking HAART in Burkina Faso. METHODS: Participants were followed for a total of 12 biweekly visits before and after randomization. The presence and frequency of genital and plasma HIV-1 RNA, and of genital HSV-2 were assessed using summary measures, adjusting for baseline values. Random effect linear regression models were used to assess the impact of treatment on genital and plasma viral loads among visits with detectable virus. RESULTS: Sixty women were enrolled into the trial. Their median CD4 lymphocyte count was 228 cells/μl, and 83% had undetectable plasma HIV-1 RNA at baseline. Valacyclovir reduced the proportion of visits with detectable genital HSV-2 DNA [odds ratio (OR) 0.37, 95% confidence interval (CI) 0.13, 1.05], but had no significant impact on the frequency (OR 0.90, 95% CI 0.31, 2.62) or quantity (reduction of 0.33 log copies/ml, 95% CI -0.81, 0.16) of genital HIV-1 RNA. However, according to pre-defined secondary analyses restricted to women who shed HIV-1 at least once in the baseline phase, valacyclovir reduced both the proportion of visits with detectable HIV-1 shedding (OR 0.27, 95% CI 0.07, 0.99) and the quantity of genital HIV-1 RNA during these visits (-0.71 log10 copies/ml, 95% CI -1.27, -0.14). CONCLUSION: HSV-2 facilitates residual genital HIV-1 replication among dually infected women taking HAART despite HIV-1 suppression at the systemic level. © 2006 Lippincott Williams & Wilkins, Inc.
Authors & Co-Authors
Ouédraogo, Abdoulaye V.
Unknown Affiliation
Nagot, Nicolas
Unknown Affiliation
Vergne, Laurence
Unknown Affiliation
Konaté, Issouf
Unknown Affiliation
Weiss, Helen Anne
Unknown Affiliation
Defer, Marie Christine
Unknown Affiliation
Foulongne, Vincent
Unknown Affiliation
Sanon, Anselme
Unknown Affiliation
Andonaba, Jean Baptiste
Unknown Affiliation
Segondy, Michel
Unknown Affiliation
Mayaud, Philippe C.
Unknown Affiliation
van de Perre, Philippe
Unknown Affiliation
Statistics
Citations: 102
Authors: 12
Affiliations: 5
Identifiers
Doi:
10.1097/QAD.0b013e328010238d
Research Areas
Disability
Genetics And Genomics
Infectious Diseases
Sexual And Reproductive Health
Study Design
Randomised Control Trial
Case-Control Study
Study Approach
Quantitative
Study Locations
Burkina Faso
Participants Gender
Female